Lubiprostone

DEA Class; Rx

Common Brand Names; Amitiza

• IBS Agents; 
• Laxatives, Other

Hypersensitivity

Mechanical GI obstruction

• Nausea (8-29%)
• Diarrhea (7-12%)
• Headache (2-11%)
• Abdominal pain (4-8%)
• Abdominal distension (3-6%)
• Flatulence (4-6%)
• Vomiting (3%)
• Loose stools (3%)
• Edema (1-3%)
• Abdominal discomfort (1-3%)
• Dizziness (3%)
• Chest discomfort/pain (2%)
• Dyspnea (2%)
• Dyspepsia (2%)
• Fatigue (2%)
• Dry mouth (1%)

In patients with symptoms suggestive of mechanical GI obstruction, perform a thorough evaluation to confirm the absence of an obstruction prior to initiating therapy (see Contraindications)

Potential for acute dyspnea described as sensation of chest tightness and difficulty breathing within 30-60 minutes after the first dose; instruct patients to contact healthcare provider if dyspnea occurs

Avoid use in patients with severe diarrhea; instruct patients of potential for diarrhea to occur during treatment

May cause nausea and diarrhea (taking with food reduces chance of nausea); dose adjustment recommended

Syncope and hypotension reported, some of which required hospitalization; most cases occurred in patients taking 24 mcg twice daily and some occurred within hour after taking first dose or subsequent doses; patients should be aware of risk of syncope and hypotension during treatment and other adverse reactions, such as diarrhea or vomiting may increase this risk

Following oral administration, concentrations of lubiprostone in plasma are below the level of quantitation; however, one of the metabolites, M3, has measurable systemic concentrations

No data are available on the presence in human milk of the refect on milk production